Laboratory Corp. of America (NYSE:LH) had its target price trimmed by SunTrust Banks to $175.00 in a research report released on Monday morning, The Fly reports. The brokerage currently has a buy rating on the medical research company’s stock.

Several other research firms have also recently commented on LH. Deutsche Bank decreased their price target on shares of Laboratory Corp. of America from $195.00 to $190.00 and set a hold rating on the stock in a research note on Monday, August 20th. Robert W. Baird decreased their price target on shares of Laboratory Corp. of America from $205.00 to $190.00 and set an outperform rating on the stock in a research note on Thursday, October 25th. Mizuho reissued a neutral rating on shares of Laboratory Corp. of America in a research note on Wednesday, September 19th. Morgan Stanley decreased their price target on shares of Laboratory Corp. of America from $202.00 to $180.00 and set an overweight rating on the stock in a research note on Monday. Finally, Canaccord Genuity cut shares of Laboratory Corp. of America from a buy rating to a hold rating and decreased their price target for the company from $190.00 to $162.00 in a research note on Thursday, October 25th. Two analysts have rated the stock with a sell rating, eight have given a hold rating and nine have given a buy rating to the company’s stock. The stock currently has a consensus rating of Hold and an average price target of $182.50.

Shares of Laboratory Corp. of America stock opened at $143.33 on Monday. The company has a current ratio of 1.55, a quick ratio of 1.44 and a debt-to-equity ratio of 0.83. The stock has a market cap of $14.70 billion, a price-to-earnings ratio of 14.93, a PEG ratio of 1.39 and a beta of 0.99. Laboratory Corp. of America has a 1-year low of $142.40 and a 1-year high of $190.35.

Laboratory Corp. of America (NYSE:LH) last released its quarterly earnings results on Wednesday, October 24th. The medical research company reported $2.74 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $2.88 by ($0.14). Laboratory Corp. of America had a net margin of 13.27% and a return on equity of 17.13%. The company had revenue of $2.83 billion for the quarter, compared to the consensus estimate of $2.84 billion. During the same period last year, the company earned $2.46 earnings per share. Laboratory Corp. of America’s revenue for the quarter was up 8.0% compared to the same quarter last year. As a group, equities analysts anticipate that Laboratory Corp. of America will post 11.03 EPS for the current year.

In related news, Director Kerrii B. Anderson sold 3,700 shares of the stock in a transaction that occurred on Monday, November 5th. The shares were sold at an average price of $163.29, for a total value of $604,173.00. Following the transaction, the director now directly owns 21,795 shares in the company, valued at $3,558,905.55. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director R Sanders Williams sold 350 shares of the stock in a transaction that occurred on Tuesday, November 27th. The shares were sold at an average price of $162.14, for a total transaction of $56,749.00. Following the completion of the transaction, the director now owns 7,886 shares in the company, valued at $1,278,636.04. The disclosure for this sale can be found here. Corporate insiders own 0.73% of the company’s stock.

A number of hedge funds and other institutional investors have recently made changes to their positions in LH. Legacy Financial Advisors Inc. raised its holdings in Laboratory Corp. of America by 763.9% in the third quarter. Legacy Financial Advisors Inc. now owns 622 shares of the medical research company’s stock worth $108,000 after purchasing an additional 550 shares during the period. Migdal Insurance & Financial Holdings Ltd. raised its holdings in Laboratory Corp. of America by 7,033.3% in the second quarter. Migdal Insurance & Financial Holdings Ltd. now owns 642 shares of the medical research company’s stock worth $115,000 after purchasing an additional 633 shares during the period. Fort L.P. acquired a new stake in Laboratory Corp. of America in the second quarter worth $118,000. Rational Advisors LLC raised its holdings in Laboratory Corp. of America by 4,966.7% in the third quarter. Rational Advisors LLC now owns 760 shares of the medical research company’s stock worth $132,000 after purchasing an additional 745 shares during the period. Finally, NuWave Investment Management LLC raised its holdings in Laboratory Corp. of America by 5,786.7% in the third quarter. NuWave Investment Management LLC now owns 883 shares of the medical research company’s stock worth $154,000 after purchasing an additional 868 shares during the period. Institutional investors and hedge funds own 91.68% of the company’s stock.

About Laboratory Corp. of America

Laboratory Corporation of America Holdings operates as an independent clinical laboratory company worldwide. It operates through two segments, LabCorp Diagnostics and Covance Drug Development. It offers a range of clinical laboratory tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, Pap tests, hemoglobin A1C, prostate-specific antigen, tests for sexually-transmitted diseases, hepatitis C tests, vitamin D, microbiology cultures and procedures, and alcohol and other substance-abuse tests that are used by hospitals, physicians and other healthcare providers and commercial clients to assist in the diagnosis, monitoring and treatment of diseases and medical conditions through the examination of substances in blood, tissues, and other specimens.

Recommended Story: Earnings Reports

The Fly

Analyst Recommendations for Laboratory Corp. of America (NYSE:LH)

Receive News & Ratings for Laboratory Corp. of America Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Laboratory Corp. of America and related companies with MarketBeat.com's FREE daily email newsletter.